Find disease awareness content and relevant supporting materials

Background: Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Novartis announced that results from the pivotal Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published...

Novartis announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic...

Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of people living with psoriatic arthritis...

Methotrexate is known to be safe and efficacious in the management of rheumatoid arthritis and psoriasis and thus has been used for the management of psoriatic arthritis despite a lack of evidence to support efficacy in psoriatic arthritis from randomized controlled trials.

While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities.

Novartis, announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira (adalimumab) in patients with active psoriatic arthritis...

Psoriasis (PsO) is an inflammatory disorder characterized by proliferation of keratinocytes, and it may be associated with a systemic inflammatory articular disorder, psoriatic arthritis (PsA).

To assess the comparative effectiveness and safety of novel biologic therapies in psoriatic arthritis (PsA) and to establish the position of the non-anti-tumor necrosis factor α (TNF-α) biologic drugs in the treatment regimen of the disease.

The UK's National Institute for Health and Care Excellence is supporting use of Cosentyx (secukinumab), from Novartis, alone, or in...